Jabs D A, Dunn J P, Enger C, Forman M, Bressler N, Charache P
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Md., USA.
Arch Ophthalmol. 1996 Jul;114(7):809-14. doi: 10.1001/archopht.1996.01100140023002.
To determine the prevalence of cytomegalovirus (CMV) isolates resistant to ganciclovir sodium or foscarnet sodium at the time of diagnosis of CMV retinitis, prior to the initiation of therapy.
Prospective epidemiologic study.
An acquired immunodeficiency syndrome ophthalmology clinic.
Patients with acquired immunodeficiency syndrome and newly diagnosed CMV retinitis.
Culturing blood and urine samples for CMV and testing of all positive isolates for sensitivity to ganciclovir and foscarnet.
Prevalence of the following: blood culture isolates resistant to ganciclovir (inhibitory concentration 50% [IC50] > 5.5 mumol/L) or foscarnet (IC50 > 400 mumol/L) and urine culture isolates resistant to ganciclovir or foscarnet.
Forty-nine patients were enrolled during a 13-month period. Forty-four patients had blood culture samples that could be evaluated; of these, 66% were positive (59% of patients). Thirty-four patients had urine cultures that were evaluable; of these, 82% were positive (57% of patients). Overall, 78% of patients had either a urine or blood culture sample positive for CMV. No blood culture isolates were resistant to ganciclovir, and only 1 urine culture isolate (2% of patients) was resistant to ganciclovir. Three percent of blood culture isolates and 4% of urine culture isolates (2% and 2% of patients, respectively) were resistant to foscarnet. Overall, 4% of patients had either a blood or urine culture isolate resistant to foscarnet.
Resistance to ganciclovir or foscarnet at the time of diagnosis of CMV retinitis is uncommon.
在开始治疗前,确定巨细胞病毒(CMV)视网膜炎诊断时对更昔洛韦钠或膦甲酸钠耐药的CMV分离株的患病率。
前瞻性流行病学研究。
一家获得性免疫缺陷综合征眼科诊所。
患有获得性免疫缺陷综合征且新诊断为CMV视网膜炎的患者。
对血液和尿液样本进行CMV培养,并对所有阳性分离株进行更昔洛韦和膦甲酸钠敏感性检测。
以下情况的患病率:对更昔洛韦(抑制浓度50%[IC50]>5.5μmol/L)或膦甲酸钠(IC50>400μmol/L)耐药的血培养分离株,以及对更昔洛韦或膦甲酸钠耐药的尿培养分离株。
在13个月期间纳入了49例患者。44例患者有可评估的血培养样本;其中66%呈阳性(占患者的59%)。34例患者有可评估的尿培养;其中82%呈阳性(占患者的57%)。总体而言,78%的患者CMV血培养或尿培养样本呈阳性。没有血培养分离株对更昔洛韦耐药,只有1例尿培养分离株(占患者的2%)对更昔洛韦耐药。3%的血培养分离株和4%的尿培养分离株(分别占患者的2%和2%)对膦甲酸钠耐药。总体而言,4%的患者血培养或尿培养分离株对膦甲酸钠耐药。
CMV视网膜炎诊断时对更昔洛韦或膦甲酸钠耐药的情况并不常见。